MAI Capital Management Has $1.99 Million Holdings in aTyr Pharma, Inc. $ATYR

Key Points

• MAI Capital Management significantly increased its stake in aTyr Pharma by 306,100% in the first quarter, owning approximately 0.74% of the company worth nearly $2 million.
• Brokerage houses have given mixed ratings on aTyr Pharma, with Wells Fargo raising its target price to $25 while Wall Street Zen downgraded the stock to a "sell" rating.
• aTyr Pharma's stock is currently priced at $5.65, with a market cap of around $553.64 million, amid predictions of further losses in earnings per share for the current fiscal year.

MAI Capital Management boosted its holdings in aTyr Pharma, Inc. (NASDAQ:ATYR - Free Report) by 306,100.0% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 658,330 shares of the company's stock after buying an additional 658,115 shares during the period. MAI Capital Management owned approximately 0.74% of aTyr Pharma worth $1,988,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the business. OMERS ADMINISTRATION Corp lifted its holdings in aTyr Pharma by 7.3% in the first quarter. OMERS ADMINISTRATION Corp now owns 148,100 shares of the company's stock valued at $447,000 after buying an additional 10,100 shares during the period. Erste Asset Management GmbH acquired a new stake in aTyr Pharma in the first quarter worth $1,812,000. Wellington Management Group LLP acquired a new stake in aTyr Pharma in the first quarter worth $510,000. XTX Topco Ltd raised its holdings in aTyr Pharma by 74.9% in the first quarter. XTX Topco Ltd now owns 19,556 shares of the company's stock worth $59,000 after purchasing an additional 8,374 shares during the period. Finally, GSA Capital Partners LLP raised its holdings in aTyr Pharma by 21.1% in the first quarter. GSA Capital Partners LLP now owns 332,324 shares of the company's stock worth $1,004,000 after purchasing an additional 57,898 shares during the period. 61.72% of the stock is currently owned by institutional investors and hedge funds.

aTyr Pharma Price Performance

Shares of aTyr Pharma stock traded up $0.14 on Friday, reaching $5.61. 3,928,278 shares of the stock were exchanged, compared to its average volume of 3,970,087. The firm's 50 day moving average is $5.34 and its 200-day moving average is $4.33. The firm has a market cap of $549.71 million, a PE ratio of -7.01 and a beta of 1.01. aTyr Pharma, Inc. has a one year low of $1.67 and a one year high of $7.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.63 and a current ratio of 5.63.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.04). As a group, analysts anticipate that aTyr Pharma, Inc. will post -0.91 EPS for the current fiscal year.

Analyst Ratings Changes

ATYR has been the subject of several research reports. Wells Fargo & Company increased their price objective on shares of aTyr Pharma from $17.00 to $25.00 and gave the stock an "overweight" rating in a research report on Friday, June 20th. Wall Street Zen downgraded shares of aTyr Pharma from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. HC Wainwright reissued a "buy" rating and issued a $35.00 price objective on shares of aTyr Pharma in a report on Wednesday, June 4th. Finally, Jefferies Financial Group boosted their price objective on shares of aTyr Pharma from $9.00 to $17.00 and gave the company a "buy" rating in a report on Friday, August 22nd. One research analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company's stock. According to data from MarketBeat, aTyr Pharma presently has an average rating of "Buy" and a consensus target price of $23.25.

aTyr Pharma Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.